可用于纵向化疗与免疫治疗研究的自发性黑色素瘤小鼠模型
研究使用完全免疫健全的TGS转基因小鼠模型,该模型由正常神经元受体mGluR1异位表达驱动自发性转移性黑色素瘤,评估长达8个月的纵向治疗反应。结果显示troriluzole和/或抗PD-1治疗改善雄性小鼠生存,与肿瘤-间质界面CD8+ T细胞和CD11b+髓系细胞群体差异相关,存在性别偏倚的治疗反应。
要点
- TGS小鼠模型可纵向评估长达8个月的黑色素瘤治疗反应。
- troriluzole和/或抗PD-1治疗改善雄性小鼠生存,存在性别偏倚。
- 生存改善与肿瘤-间质界面CD8+ T细胞和CD11b+髓系细胞差异相关。
核心结论
- TGS小鼠模型是免疫健全环境中评估黑色素瘤治疗方案的响应性且可操作的系统。
研究设计与样本
- 使用完全免疫健全的TGS转基因小鼠模型,由正常神经元受体mGluR1异位表达驱动自发性转移性黑色素瘤。
- 评估长达8个月的纵向治疗反应,治疗为谷氨酸能信号抑制剂troriluzole(利鲁唑的前药)联合抗PD-1抗体。
主要发现
- troriluzole和/或抗PD-1治疗改善雄性小鼠生存,存在性别偏倚的治疗反应。
- 生存改善与肿瘤-间质界面CD8+ T细胞和CD11b+髓系细胞群体的差异相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mouse models that reflect human disorders provide invaluable tools for the translation of basic science discoveries to clinical therapies. However, many of these in vivo therapeutic studies are short term and do not accurately mimic patient conditions. In this study, we used a fully immunocompetent, transgenic mouse model, TGS, in which the spontaneous development of metastatic melanoma is driven by the ectopic expression of a normal neuronal receptor, mGluR1, as a model to assess longitudinal treatment response (up to 8 months) with an inhibitor of glutamatergic signaling, troriluzole, which is a prodrug of riluzole, plus an antibody against PD-1, an immune checkpoint inhibitor. Our results reveal a sex-biased treatment response that led to improved survival in troriluzole and/or anti-PD-1-treated male mice that correlated with differential CD8+ T cells and CD11b+ myeloid cell populations in the tumor-stromal interface, supporting the notion that this model is a responsive and tractable system for evaluating therapeutic regimens for melanoma in an immunocompetent setting.
引用
- Eddy K, Gupta K, Pelletier JC, et al. A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study. J Invest Dermatol. 2023. PMID: 36997110. doi:10.1016/j.jid.2023.03.1664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。